LONG BEACH, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Obagi Medical Products, Inc. , a leader in topical aesthetic and therapeutic skin health systems, today announced the introduction of ELASTIderm(TM) Decolletage System. Formulated with a unique combination of ingredients, it is the only system designed to treat mottled hyperpigmentation, including age spots and freckles, while reducing the appearance of fine lines and wrinkles by replenishing elasticity and building collagen on the chest and neck area (also known as decolletage).
The ELASTIderm(TM) Decolletage System is the newest addition to the trusted ELASTIderm family of physician-dispensed skincare products.
“The new ELASTIderm Decolletage System applies the unique and efficacious technology that exists in our ELASTIderm Eye Cream to address an area in the aesthetics market that is a real source of frustration for so many women,” said Rick Kozloski, Vice President, Marketing and Dermatology for Obagi Medical Products. “The delicate neck and chest area is often untreated in the anti-aging process and this new system can assist skin care professionals in providing the total rejuvenating results their patients want.”
The ELASTIderm(TM) Decolletage System consists of two clinically proven topical skin treatments -- ELASTIderm Skin Lightening Complex and ELASTIderm Wrinkle Reducing Lotion. The ELASTIderm Skin Lightening Complex is formulated with 4% hydroquinone to aid in the gradual lightening of hyperpigmented skin conditions. The ELASTIderm Wrinkle Reducing Lotion is formulated with a proprietary bi-mineral complex with malonic acid that helps replenish elasticity and build collagen.
“The ELASTIderm(TM) Decolletage System uses Obagi Medical Product’s exclusive Penetrating Therapeutics(TM), an effective patented technology that allows for greater penetration of an active agent across the skin barrier to stimulate functional elasticity and resilient strength of the skin,” said Steve Carlson, President and Chief Executive Officer of Obagi Medical Products. “We’ve designed the system so that each ingredient can play a critical role in helping to restore elasticity and collagen to help stimulate the production of healthy skin cells, which bolsters Obagi’s position as the leader in elastin science.”
The ELASTIderm(TM) Decolletage System is an easy to use two-step system which should be applied once in the morning and once in the evening or as directed by a skin care professional. The ELASTIderm(TM) Decolletage System is available through dermatologists’ and plastic surgeons’ offices nationwide. To locate a physician who carries the ELASTIderm(TM) Decolletage System, log onto www.obagi.com.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris, fine lines, wrinkles and sun damage. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm eye treatment and Obagi CLENZIderm M.D. acne therapeutic systems, 2007; and a formulation of CLENZIderm for normal to dry skin, July 2007. Obagi’s products are only available through physicians. Visit www.obagi.com for information.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words “believes,” “expects,” “may,” “will,” “should,” “potential,” “anticipates,” “plans,” or “intends” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
CONTACT: Dave Schemelia of HealthSTAR Public Relations, +1-646-722-8819,
or cell, +1-609-468-9325, dschemelia@healthstarpr.com; Ina McGuinness or
Lena Adams of ICR, Inc. +1-310-954-1100, for Obagi Medical Products, Inc.
Web site: http://www.obagi.com/